You are here

Tazocin Intervention Study

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Peking, , 100730 China
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bacterial Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- All patients admitted or transferred to the ICU/pulmonary/Infection units

- Patients of either sex, 18 years of age or older Patients who stay in units less than
48 hours will not be enrolled.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- All patients admitted or transferred to the ICU/pulmonary/Infection units

- Patients of either sex, 18 years of age or older Patients who stay in units less than
48 hours will not be enrolled.

NCT00478855
Pfizer
Completed
Tazocin Intervention Study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Respiratory Tract Infections
NCT03529773
All Genders
18+
Years
Multiple Sites
Pneumococcal Infections
NCT03512288
All Genders
0+
Years
Multiple Sites
Cryptococcal Meningitis, HIV Infections
NCT00002294
All Genders
18+
Years
Multiple Sites
Tazocin Intervention Study
Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria
  1. To determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization and infection.
  2. To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre-and post-intervention in the selected medical centers.
Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Bacterial Infections
Drug: Tazocin (Piperacillin/Tazobactem)
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
500
June 2007
Not Provided

Inclusion Criteria:

  • All patients admitted or transferred to the ICU/pulmonary/Infection units
  • Patients of either sex, 18 years of age or older Patients who stay in units less than 48 hours will not be enrolled.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
China
 
 
NCT00478855
0910X-102105
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
December 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now